Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $14.53 per share for ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7.Stay Ahead of the ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...